Vanderbilt University Takes $1.48 Million Position in Boston Scientific Corporation $BSX

Key Points

• Vanderbilt University has acquired a new position in Boston Scientific Corporation, purchasing 13,780 shares valued at approximately $1.48 million.
• Several hedge funds have also increased their stakes in Boston Scientific, with notable increases from Empirical Financial Services and J. Safra Sarasin Holding, reflecting a strong institutional interest.
• Boston Scientific reported a 22.8% year-over-year increase in quarterly revenue, achieving earnings of $0.75 per share, surpassing expectations of $0.72.

Vanderbilt University acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 13,780 shares of the medical equipment provider's stock, valued at approximately $1,480,000.

Other hedge funds have also recently made changes to their positions in the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in Boston Scientific by 21.5% in the 2nd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 26,471 shares of the medical equipment provider's stock valued at $2,843,000 after buying an additional 4,690 shares during the period. Synergy Asset Management LLC raised its stake in Boston Scientific by 15.1% during the 2nd quarter. Synergy Asset Management LLC now owns 13,730 shares of the medical equipment provider's stock worth $1,475,000 after acquiring an additional 1,801 shares in the last quarter. Hilltop National Bank acquired a new position in Boston Scientific in the second quarter valued at $208,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Boston Scientific by 12.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 242,492 shares of the medical equipment provider's stock valued at $26,046,000 after purchasing an additional 26,775 shares during the period. Finally, J. Safra Sarasin Holding AG increased its stake in Boston Scientific by 23.2% in the second quarter. J. Safra Sarasin Holding AG now owns 200,649 shares of the medical equipment provider's stock valued at $21,552,000 after purchasing an additional 37,784 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BSX. Raymond James Financial boosted their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Barclays upped their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an "overweight" rating in a report on Thursday. BTIG Research upped their price objective on shares of Boston Scientific from $127.00 to $132.00 and gave the company a "buy" rating in a research note on Wednesday. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Finally, Wells Fargo & Company upped their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $120.79.

Boston Scientific Trading Up 0.5%

Shares of NYSE:BSX opened at $96.36 on Friday. The company has a market cap of $142.78 billion, a PE ratio of 57.36, a P/E/G ratio of 2.31 and a beta of 0.61. The company's 50-day moving average price is $103.10 and its 200 day moving average price is $102.06. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.